On Jul. 6, 2020, AIM ImmunoTech announced that it had signed a material transfer and research agreement with Japan’s National Institute of Infectious Diseases and Shionogi & Co., in order to test AIM’s drug Ampligen as a potential adjuvant therapy for COVID-19. Under the agreement, AIM will provide Ampligen samples for various research projects. The details of all preclinical and clinical results will remain confidential until released by NIID and Shionogi.